Eli Lilly and Company

URI: https://gptkb.org/entity/Eli_Lilly_and_Company

GPTKB entity

AI-created image

Statements (52)

Predicate	Object
gptkbp:instanceOf	gptkb:biotechnology
gptkbp:CEO	gptkb:David_A._Ricks
gptkbp:country	gptkb:United_States
gptkbp:CUSIP	532457108
gptkbp:dividendPaying	yes
gptkbp:foundedBy	gptkb:Eli_Lilly
gptkbp:foundedYear	1876
gptkbp:headquartersLocation	gptkb:Indianapolis,_Indiana,_United_States
https://www.w3.org/2000/01/rdf-schema#label	Eli Lilly and Company
gptkbp:industry	pharmaceuticals
gptkbp:ISIN	US5324571083
gptkbp:logo	Eli Lilly and Company logo.svg
gptkbp:marketCap	over $500 billion (2024)
gptkbp:memberOf	gptkb:Pharmaceutical_Research_and_Manufacturers_of_America
gptkbp:NAICS	325412
gptkbp:netIncome	$5.2 billion (2022)
gptkbp:notableEmployee	gptkb:George_H._Hitchings gptkb:Paul_Janssen
gptkbp:notableEvent	Acquired ImClone Systems in 2008 Developed first commercially available insulin Developed first mass-produced polio vaccine Launched Mounjaro (tirzepatide) in 2022 Spun off Elanco in 2018
gptkbp:notableProduct	gptkb:Alimta gptkb:Cymbalta gptkb:Emgality gptkb:Humalog gptkb:Mounjaro gptkb:Prozac gptkb:Trulicity gptkb:Verzenio gptkb:Zyprexa
gptkbp:numberOfEmployees	approximately 41,000 (2023)
gptkbp:parentCompany	none
gptkbp:rank	gptkb:Fortune_500
gptkbp:researchInterest	gptkb:diabetes immunology neuroscience oncology
gptkbp:revenue	$28.5 billion (2022)
gptkbp:servesArea	worldwide
gptkbp:SIC	2834
gptkbp:stockExchange	gptkb:NYSE
gptkbp:stockSymbol	gptkb:LLY
gptkbp:subsidiary	gptkb:ImClone_Systems Elanco (spun off in 2018)
gptkbp:type	gptkb:public_company
gptkbp:website	https://www.lilly.com/
gptkbp:bfsParent	gptkb:Eli_Lilly_Award_in_Biological_Chemistry gptkb:Sigilon_Therapeutics gptkb:Indianapolis,_Indiana
gptkbp:bfsLayer	4